Open Access

Similar dose-dependence of motor neuron cell death caused by wild type human TDP-43 and mutants with ALS-associated amino acid substitutions

Journal of Biomedical Science201320:33

DOI: 10.1186/1423-0127-20-33

Received: 13 May 2011

Accepted: 3 May 2013

Published: 30 May 2013

Abstract

Background

TDP-43, a multi-functional DNA/ RNA-binding protein encoded by the TARDBP gene, has emerged as a major patho-signature factor of the ubiquitinated intracellular inclusions (UBIs) in the diseased cells of a range of neurodegenerative diseases. Mutations in at least 9 different genes including TARDBP have been identified in ALS with TDP-43 (+)-UBIs. Thus far, the pathogenic role(s) of the more than 30 ALS-associated mutations in the TARDBP gene has not been well defined.

Results

By transient DNA transfection studies, we show that exogenously expressed human TDP-43 (hTDP-43), either wild type (WT) or 2 different ALS mutant (MT) forms, could cause significantly higher apoptotic death rate of a mouse spinal motor neuron-like cell line (NSC34) than other types of cells, e.g. mouse neuronal Neuro2a and human fibroblast HEK293T cells. Furthermore, at the same plasmid DNA dose(s) used for transfection, the percentages of NSC34 cell death caused by the 2 exogenously expressed hTDP-43 mutants are all higher than that caused by the WT hTDP-43. Significantly, the above observations are correlated with higher steady-state levels of the mutant hTDP-43 proteins as well as their stabilities than the WT.

Conclusions

Based on these data and previous transgenic TDP-43 studies in animals or cell cultures, we suggest that one major common consequence of the different ALS-associated TDP-43 mutations is the stabilization of the hTDP-43 polypeptide. The resulting elevation of the steady state level of hTDP-43 in combination with the relatively low tolerance of the spinal motor neurons to the increased amount of hTDP-43 lead to the neurodegeneration and pathogenesis of ALS, and of diseases with TDP-43 proteinopathies in general.

Keywords

TDP-43 ALS Mutations Protein stability Spinal motor neuron cells Apoptosis

Background

The TAR-DNA-binding protein 43 (TDP-43)-encoding gene, TARDBP, is well conserved among the multicellular organisms from C. elegans to human [1, 2]. Of the multiple isoforms encoded by the TARDBP gene, the 43 kDa TDP-43 protein is the most abundant one expressed in all tissues [3, 4], mainly in the nucleus but some also residing in the cytoplasm [4, 5]. TDP-43 appears to be a general transcription repressor [3, 5, 6], a splicing factor [7, 8], and a neuronal activity-responsive factor [4]. Not surprisingly, intact TARDBP gene is indispensible for normal early development of the mouse embryos [912]. Lately, TDP-43 has emerged as the major patho-signature protein of the ubiquitinated intracellular inclusions (UBIs) in the diseased brain/ neuron cells of a range of neurodegenerative diseases, two major ones being the frontotemporal lobar degeneration with ubiquitin-positive, tau- and α-synuclein -negative inclusions (FTLD-U) and amyotrophic lateral sclerosis (ALS) [1315]. Biochemical analyses have revealed that human TDP-43 (hTDP-43) is promiscuously modified/ processed in the affected regions of the brains and spinal cords of the FTLD-U and ALS patients, respectively [1315]. Loss-of-function of TDP-43 as well as gain-of-cytotoxicity, as the result of the promiscuous modifications of TDP-43, have been suggested to lead to the pathogenesis of FTLD-U and as ALS with the TDP-43(+) UBIs [6, 1518] and references therein].

The molecular and cellular basis for the pathogenesis of either ALS or FTLD-U is poorly understood yet. Mutations in 11 different genes, including the long studied superoxide dismutase 1 (SOD 1) and TARDBP, have been identified to be associated with 10% of ALS [19], which is a disease with age-dependent degeneration of the spinal cord motor neurons [20]. Furthermore, the majority of the ALS cases, including those the disease genes of which have not been identified yet, are signalized with the TDP-43(+)-UBIs [21]. Interestingly, more than 30 different ALS-associated TARDBP mis-sense substitutions have been identified, almost all of which are mapped in the glycine-rich domain of TDP-43 [15, 16, 22]. A number of DNA transfection/ microinjection experiments in cell cultures or cell lines have been carried out to analyze the cyto-toxicities of different ALS-associated hTDP-43 mutants in comparison to the wild type [2327]. For instance, Q331K and M337V accelerate spontaneous hTDP-43 aggregation in yeast cells [23]. On the other hand, while both the wild type hTDP-43 and 3 mutant forms of hTDP-43 (A315T, G348C, and A382T) induce death of primary motor neurons but not cells from Neuro2a and COS cell lines, the mutant forms are more potent than the wild type hTDP-43 in the induction of neuron death [24]. hTDP-43A315T is also more toxic to the primary rat cortical neurons than the wild type hTDP-43 [25]. Furthermore, hTDP-43Q331K and TDP-43M337V induce oxidative injury of the motor neuron-like NSC34 cells [26]. One unanswered question from these studies is why, in general, the ALS-associated mutants of hTDP-43 are more cyto-toxic than the wild type hTDP-43. Notably, in most, if not all, of the above mentioned cell culture and cell line studies, the relative cellular levels of the exogenous proteins were not quantified and compared between the wild type and mutant hTDP-43.

In the following, we show that two randomly chosen ALS mis-sense mutations of the TARDBP gene both increase the stability of the TDP-43 polypeptide in motor neuron-like cells as well as in non-motor neuron cells. In addition, the mutant hTDP-43 polypeptides as well as the wild type hTDP-43 induce significant apoptosis of motor neuron-like cells, but much less so in non-motor neuron cells, in a dose-dependent manner. Thus, the major role of the ALS-associated hTDP-43 mutations appears to be the enhancement of the steady-state level of hTDP-43 through stabilization of the polypeptide in the spinal motor neurons, which have a low tolerance to the elevated cellular level of TDP-43 in comparison to the non-motor neuron cells.

Methods

Construction of expression plasmids

Wild type (WT) human hTDP-43 with addition of a Myc epitope tag to its 3’-end was generated by PCR of human brain cDNA using the following primers: forward, 5'-CCG CTC GAG CGG ATG TCT GAA TAT ATT CGG GTA AC -3'; reverse, 5'-TCT AGA GCT ACA GAT CCT CTT CCG AGA TGA GTT TTT GTT CCA TTC CCC AGC CAG AAG AC-3'. The A315T and N390D mutations were introduced into the WT cDNA by site-directed mutagenesis using the QuikChange® Site-Directed Mutagenesis Kit (Strategene). The three hTDP-43 cDNAs were first cloned into the pGEM-T vector (Promega, Madison, WI). Following sequence confirmation, the cDNA inserts were subcloned into the XhoI/ XbaI sites of a pEF vector. Experimental research that is reported in the manuscript was performed with the approval of an appropriate ethics committee.

Antibodies

The commercial antibodies used in this study included a rabbit anti-TDP-43 polyclonal antibody (pAb) raised against a.a 1–260 of human TDP-43 and recognizing human as well as mouse TDP-43 (Gene Tex), a human specific mouse monoclonal antibody (mAb) against the same TDP-43 sequence (2E2-D3) (Abnova), anti-Myc mAb (LTK), anti-α-tubulin (Sigma), anti-cleaved caspase 3 (Asp175) (Ac-cap3) (Cell Signaling), and anti-Hsp70 (Chmicon).

Cell cultures and DNA transfection

NSC34 cells were maintained in DMEM (Invitrogen) supplemented with 10% FBS (Invitrogen) and 1% antibiotics (100 IU/mL penicillin and 100 g/mL streptomycin). Neuro2a cells were maintained in MEM (Invitrogen) supplemented with 10% FBS (Invitrogen), 1% antibiotics, and 1% sodium pyruvate (Invitrogen). SHSY5Y cells were maintained in DMEM/F12 (Invitrogen) with 10% FBS (Invitrogen), 1% antibiotics, and 1% sodium pyruvate (Invitrogen). The cells were transfected with the empty pEF vector and the expression plasmids, respectively, using Lipofectamine 2000 transfection reagent (Invitrogen) following the manufacturer’s protocol. The amount of the plasmid DNA used in each transfection was kept at 20 μg/106 cells by supplement with the pEF vector DNA. After transfection for different hrs, the cells were harvested and analyzed by Western blotting. In general, under the conditions used by us, the transfection efficiencies of NSC34, Neuro2A, SHSY5Y, and HEK293 were approximately 50%, 70%, 70%, and 90%, respectively.

Cell death assay with use of Caspase-Glo 3/7

After incubation with the transfectants, the cells were split and seeded with two different densities, 2 × 103 cells/well and 8 × 103 cells/well, and allowed to grow for 24 hr and 72 hr, respectively. On the average, the cells were at 30% confluency before the assay. For the assay, Caspase-Glo 3/7 reagent (Promega) was added to all the wells in a 1:1 ratio following the manufacturer's instructions. Cells with addition of 5 μM staurosporine (0.1% final DMSO; Sigma) for 6 hr were used as a positive control [28]. After shaking at room temperature for 30 min, the lysates were analyzed with an Microplate Reader (Vector). A total of 3 replicates were performed. To determine the fold changes of caspase 3/ 7 activities, four independent experiments were carried out. The data were expressed as means ± SD. The differences in the caspase 3/ 7 activities among the variants were assessed by the ANOVA test. An unpaired two-tailed Student’s t-test was then used to obtain the p values associated with comparisons between the MT and WT.

Cell death assay by immunofluorescence staining

The cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS), permeabilized with 0.1% Triton X-100 (Sigma) in PBS for 5 min, blocked with 10% donkey serum in PBS for 2 hr, and incubated overnight at 4°C with the primary antibodies anti-hTDP-43 (2E2-D3), anti-Myc, and anti-cleaved caspase 3, respectively . The primary antibodies were visualized with secondary antibodies conjugated with Alexa Fluor 488 or Alexa Fluor 561 (Molecular Probe), and the nuclei were detected using DAPI (4,6-diamino-2-phenylindole). The patterns of immunofluorescence staining were analyzed in a LSM710 confocal microscope (Zeiss). For quantification of cleaved caspase-3 positive cells, several random fields/ sample were analyzed and the percentages of transfected cells displaying anti-cleaved caspase 3 staining signals and apoptotic nuclei were calculated (N=150 cells, duplicate in one experiment). To determine the percentages of dead cells, four independent experiments were carried out. The data were expressed as means ± SD. The differences in % of the Ac-cap 3-positive cells among the variants were assessed by the ANOVA test. An unpaired two-tailed Student’s t-test was then used to obtain the p values associated with comparisons between the MT and WT.

Western blot analysis

Cells were lysed in RIPA buffer (0.1% SDS, 1% Nonidet P-40, 0.5% sodium deoxycholate, 5mM EDTA, 150mM NaCl, 50mM Tris-HCl, pH 8.0) supplemented with protease inhibitors (Roche) and phosphatase inhibitors (Sigma). The protein concentrations of the lysates were measured using the Bio-Rad protein assay reagent on a Beckman Coulter DU-800 machine. The lysates were then resolved by SDS–PAGE and immunoblotted with the indicated antibodies. Quantification of the immunoblot band intensities was performed with use of the Image J software (NIH). There independent experiments on each cell line were carried out for densitometry analysis. The data were expressed as means ± SD. The differences in the relative levels of hTDP-43 among the variants were assessed by the ANOVA test. An unpaired two-tailed Student’s t-test was then used to obtain the p values associated with comparisons between the MT and WT.

Protein degradation analysis

Cells were transfected with different expression plasmids encoding Myc-tagged versions of WT hTDP-43 and the two MT hTDP-43. Cycloheximide (50 μg/ mL; Sigma) was added to the media at 40 hr post-transfection. At various time points thereafter, the transfected cells were lysed and the amounts of the Myc tagged TDP-43 proteins were measured by Western blot analysis using the anti-hTDP-43 antibody (2E2D3) or anti-Myc antibody (LTK). Four independent experiments on each cell line were carried out for densitometry analysis. The data were expressed as means ± SD. The differences in relative levels of hTDP-43 among the variants were assessed by the ANOVA test. An unpaired two-tailed Student’s t-test was then used to obtain the p values associated with comparisons between the MT and WT.

Statistical analysis

The data obtained from independent experiments are expressed as the mean ± S.D.. The differences among the variants were assessed by the ANOVA test. An unpaired two-tailed Student’s t-test was then used to obtain the p values associated with comparisons between the MT and WT.

Results and discussion

Overexpression of Wild Type (WT) or Mutant (MT) Human TDP-43 (hTDP-43) induced apoptotic death of motor neuron cells

To examine the relative cytotoxicities of WT and MT hTDP-43 in motor neuronal cells and non-motor neuronal cells, respectively, plasmids encoding the WT hTDP-43 and hTDP-43 carrying two different ALS-associated mutations (A315T and N390D) (Figure 1A) were transiently transfected into mouse NSC34, mouse Neuro2a, human HEK293T, and human SHSY5Y cells. Of these cell lines, NSC34 was established by fusion of the embryonic mouse spinal cord cells, which were enriched in the motor neurons, with mouse neuroblastoma cells [29]. It exhibited a number of motor neuron properties and was used widely as a cellular model system for motor neuron studies [30]. On the other hand, the differentiated neuron-like Neuro2a was established from a spontaneous neuronal tumor of a strain A albino mouse [31]. SHSY5Y cells was an human neuroblastoma cell line [32]. HEK 293T was an embryonic human kidney fibroblast cell line [33]. The two ALS-associated hTDP-43 mutations were chosen because of their identifications in more than one patient and by more than one group [15, 16]. As seen in Figure 1B, the sub-cellular localization of the exogenous hTDP-43 was mainly nuclear in both transfected NSC34 and Neuro2a cells. Similar patterns were observed for transfected HEK 293T and SHSY5Y cells (data not shown). Consistent with the previous studies [24, 34], the WT or MT hTDP-43 could be seen to form cytosolic aggregates in only a few percent of the transfected cells (data not shown).
Figure 1

Immunofluorescence staining analysis of NSC34 and Neuro2a cells overexpressing WT and MT hTDP-43. (A) Physical maps showing the domains of human TDP-43 (hTDP-43) and mouse TDP-43 (mTDP-43). NLS, nuclear localization signal; NES, nuclear export signal; GR, glycine-rich sequence; GQN, glycine (G), glutamine (Q) and/ or asparagine (N)-rich sequence. For hTDP-43, the cDNA inserts in the 3 expression plasmids encoding the WT and the two mutant forms of hTDP-43 are shown. The positions of the nucleotide substitutions are indicated by the stars. (B) Representative photographs showing the immunofluorescence staining patterns of transfected cells. NSC34 (upper two rows) and Neuro2a (lower two rows) cells were transfected with plasmids expressing the WT hTDP-43 and hTDP-43A315T, respectively, and analyzed by immunofluorescence staining at 48 hr post-transfection with use of the 2E2D3 antibody recognizing hTDP-43 and DAPI staining the nucleus. Note the predominant nuclear localization of the exogenous WT and MT hTDP-43 in both types of cells. Scale bar, 10 μm.

To examine the apoptotic cell death induced by overexpression of the WT hTDP-43 in comparison to the MT hTDP-43, we measured activities of the effector apoptotic caspases 3 and 7 of NSC34 (Figure 2A, left panel), Neuro2a (Figure 2A, right panel), and HEK 293T cells (data not shown) using a luminescent assay [35]. As seen, transfection of 106 cells with 5 μg of plasmids overexpressing WT hTDP-43 (Figure 2A) or wild type mouse TDP-43 (mTDP-43) (Additional file 1: Figure S1) had little effect on the caspase 3/ 7 activities. On the other hand, NSC34 cells overexpressing the MT hTDP-43 at 72 hr, but not 24 hr, post-transfection exhibited 45-70% increases of the activities of caspase 3/ 7 in comparison to the vector control (left panel, Figure 2A). In contrast, the caspase 3/ 7 activities of Neuro2a cells overexpressing the MT hTDP-43 increased by only little (right panel, Figure 2A). Result of transfected HEK 293T cells was similar to Neuro2a (data not shown). Taken together, at the same dose (5 μg/ 106 cells) of the expression plasmid(s) used for transfection, overexpression of the two MT hTDP-43 forms caused a motor neuronal cell type-specific cytotoxicity significantly higher than that by the WT hTDP-43.
Figure 2

Apoptotic assays of transfected NSC34 and Neuro2a cells. (A) Comparison of apoptotic death induced by exogenous WT and MT hTDP-43. Cell death was assayed by measurement of the activities of caspase 3/ 7 at 24 hr and 72 hr post-transfection with the expression plasmids (5 ug/ 106 cells). Mock, cells without transfection; C, cells transfected with the pEF vector; Stau. 5 uM, cells treated with 5 uM of staurosporine for 6 hr to induce apoptosis. The folds of the caspase activities relative to that of the Mock sample were calculated and shown. Note the significant increase of the caspase 3/ 7 activities in NSC34 cells (left panel), but not Neuro2a cells (right panel), induced by the two MT hTDP-43 forms at 72 hr post-transfection. (B) Comparison of plasmid dose-dependent apoptotic death induced by exogenous WT and MT hTDP-43. Apoptotic cell death was determined by immunofluorescence staining of cleaved caspase 3. The extents of apoptotic cell death of NSC34 cells and Neuro2a cells at 72 hr post-transfection with different amounts of the expression plasmids were assayed by immunofluorescence staining with the antibodies 2E2D3 and Ac-cap 3. Means of three independent experiments (S.D.) are plotted in the upper 2 panels, with the % of hTDP-43-positive cells that are also Ac-cap 3-positive as a function of the doses of transfection. Approximately 1% of cells transfected with the pEF vector were Ac-cap3 positive ( in the two plots). Representative photographs are shown below the plots, with the apoptotic nuclei/ cleaved caspase 3-positive cells indicated by the arrowheads. For both the NSC34 and Neuro2a sets, two Ac-cap 3-positive cells (the boxed areas) are magnified for better visualization. Scale bar, 10 μm. *, p< 0.05; **, p< 0.01; ***, p< 0.001.

Motor neuronal cell-specific apoptotic death induced by both MT and WT hTDP-43 were dose-dependent

To examine whether the neurotoxicity of NSC34 cells caused by the overexpressed MT hTDP-43 was dose-dependent, we transfected NSC34 and Neuro2a cells with different amounts of the individual expression plasmids. The extents of apoptotic cell death were then analyzed by immunostaining with anti-cleaved caspase 3. Interestingly, MT hTDP-43 as well as WT hTDP-43 caused apoptotic cell death of the NSC34 cells in a dose-dependent manner, with the proportion of cleaved caspase 3-positive cells increased from 4-6% at the dose of 2.5 μg plasmid/ 106 cells to 15-19% at 10 μg plasmid/ 106 cells (upper left panel, Figure 2B). Furthermore, at each dose used for transfection, both MT hTDP-43 forms showed higher toxicities than the WT. Also, the differences of the effects between MT and WT hTDP-43 increased as higher amounts of the expression plasmids were used for transfection (upper left panel, Figure 2B). Similar to Figure 2A, overexpression of either MT or WT form of hTDP-43 caused much smaller increase (~4%) of the cell mortality of Neuro2a (upper right panel, Figure 2B) or HEK 293 cells (data not shown). Interestingly, overexpression of the wild type mTDP-43 also caused the selective neuronal apoptosis of the NSC34 cells in comparison to Neuro2a cells (Additional file 2: Figure S2). These data suggested that overexpression of either WT or MT hTDP-43 could cause significantly higher cytotoxicity in the motor neuronal-type cells than non-motor neuron cells. For some reason, however, the MT hTDP-43 appeared to be more toxic to NSC34 cells than the WT hTDP-43 or WT mTDP-43.

ALS-associated hTDP-43 mutations stabilized hTDP-43 in NSC34 as well as in Neuro2a Cells

The relatively higher death incidence of NSC34 cells as caused by MT hTDP-43 than the WT hTDP-43 (Figure 2B) could be due to that ALS-associated TDP-43 mutations affecting certain motor neuronal cell-specific functions of hTDP-43 or cellular pathways. Alternatively, these mutations might exert their effects by elevating the steady-state level of the MT hTDP-43 through stabilization of the protein. Significantly, when the total cellular extracts of transfected cells were analyzed by Western blotting, the steady-state levels of the two MT hTDP-43 were indeed higher than the WT TDP-43, and this was the case over a range of the amounts of plasmid DNA used for transfection (left panel of Figure 3A and Table 1). Similar pattern was observed when the extracts of transfected Neuro2a cells were analyzed (right panel of Figure 3A and Table 1). In parallel to Additional file 2: Figure S2, the dose dependence of the steady state level of WT mTDP-43 in transfected NSC34 or Neuro2a cells was similar to WT hTDP-43 (Additional file 3: Figure S3).
Figure 3

hTDP-43 protein dose-dependent apoptotic death of NSC34 cells. (A) Higher levels of MT hTDP-43 than WT hTDP-43 at the same dose(s) of DNA transfection. NSC34 and Neuro2a cells were transfected with different doses (μg/ 106 cells) of the expression plasmids. At 72 hr post-transfection, the levels of the exogenous hTDP-43 expressed were compared by Western blotting using the anti-hTDP-43 antibody 2E2D3, with the mouse Hsp70 level as the internal control. The means of the relative levels of hTDP-43 obtained from three independent experiments (S.D.) are then plotted in the 2 panels, with the level of the WT hTDP-43 in cells with the transfection dose of 20 μg DNA/ 106 cells as 100. Note the higher levels of the MT hTDP-43 than WT hTDP-43 in both NSC34 and Neuro2a cells at all doses of transfection. *, p< 0.05; **, p< 0.01; ***, p< 0.001. (B) The % of transfected cells that were cleaved caspase 3-positive as a function of the relative amounts of hTDP-43. The plots were derived from the combined data of Figures 2 and 3A. The amounts of hTDP-43 in NSC34 cells or Neuro2a cells transfected with 20 μg of pEF-hTDP-43N390D are assigned the value of 1.

Table 1

Levels of exogenous hTDP-43 proteins relative to the endogenous mTDP-43 in transfected cells*

 

Plasmid DNA amount (μg) used for transfection of 106cells

 

1.25

2.5

5

10

20

NSC34

WT

0.26

0.56

0.73

0.87

1.1

A315T

0.54

0.77

0.80

1.0

1.3

N390D

0.61

0.86

0.93

1.3

1.5

Neuro2a

WT

0.29

0.49

0.86

1.4

1.7

A315T

0.44

0.65

1.1

1.6

1.9

N390D

0.50

0.89

1.2

1.6

2.2

* The levels of the exogenous hTDP-43 proteins relative to the endogenous mTDP-43 were measured first by Western blot analysis using the Gene Tex antibody recognizing both hTDP-43 and mTDP-43. The ratio of the intensity of the exogenous hTDP-43 to that of the endogenous mTDP-43 at each dose of the transfection was estimated and then calibrated against the average transfection efficiencies of the cells (50% for NSC34 and 70% for Neuro2a cells).

Since both the cytotoxicity of NSC34 cells caused by MT hTDP-43 (Figure 2B) and their steady-state levels (Figure 3A) were higher than WT hTDP-43 at the same dose(s) of DNA transfection, we speculated that the differences of cytotoxicities as caused by the MT and WT hTDP-43 might reflect mainly the differences of the steady-state levels of the proteins, instead of the sequence differences of the polypeptide per se. Indeed, as seen in the left panel of Figure 3B, the NSC34 cell death caused by the exogenous hTDP-43 proteins increased as a function of the relative amounts of the proteins, irrespective of whether the protein was the WT or the MT forms. As expected from the data of Figure 2B, the relatively lower cytotoxicity of the Neuro2a cells caused by the exogenous hTDP-43 remained similar over a range of the amounts of hTDP-43, WT or MT, expressed in the cells (right panel, Figure 3B).

We then examined whether the ALS-associated mutations stabilized hTDP-43 in NSC34, Neuro2a, and SHSY5Y cells. For this, we carried out cycloheximide chase experiments [36] (also see the experimental details in Methods) in these three types of cells. 106 of the cells were transfected with 2.5 μg of the individual expression plasmids and then split into different aliquots at 20 hr post-transfection. These aliquots of cells were allowed to adhere for another 20 hr and then each aliquot was treated with cycloheximide for a different period of time. As exemplified in the Western blots in Figure 4, the amounts of the WT hTDP-43 in different types of the transfected cells, i.e. NSC34 (Figure 4A), Neuro2a (Figure 4B), SHSY5Y (Figure 4C), and HEK293T (data not shown) were significantly lower than those of the two MT hTDP-43 forms at each of the time points of cycloheximide treatment. This corresponded to increases of the half-life of hTDP-43, as the result of the ALS mutations, by approximately 2 to 4 hrs (Figure 4A), 6 to 8 hrs (Figure 4B), and 6 to 8 hrs (Figure 4C), respectively. The stabilization of hTDP-43 by the ALS mutations was in consistency with the higher steady-state levels of the MT hTDP-43 proteins than the WT hTDP-43 in transfected NSC34 cells (Figure 3).
Figure 4

Increased stabilities of hTDP-43 polypeptides with ALS-associated mutations. The stabilities of the exogenous hTDP-43 in transfected NSC34 (A), Neuro2a (B), and SHSY5Y (C) cells were measured by cycloheximide chase experiments as described in Methods. The Western blots of the exogenous WT hTDP-43 and MT hTDP-43A315T in transfected cells are shown as the examples of analysis. The relative amounts of hTDP-43 at different hr of cycloheximide treatment are plotted in the upper two panels. The mean values of 3 different sets of the chase experiments are used for the plots. p< 0. in NSC34, Neuro2a, and SHSY5Y cells.

Both WT and MT hTDP-43 induced motor neuron cell death in a dose- dependent manner

The cell type-independent stabilization of hTDP-43 by A315T and N390D, as shown above, might be a general effect of most of the ALS-associated TDP-43 mutations. 3 others (Q298S, Q331K, and M337V) have been shown to stabilize hTDP-43 in HeLa cells and in primary fibroblast culture from a human patient [37]. Also, 5 other ALS-associated mutations (G298S, Q343R, G348C, N352S, and A382T) increased the protein half-life of hTDP-43 in Neuro2a cells [38]. In the latter study, it was also found that stabilization of hTDP-43 by the mutations was correlated with an early disease onset, but not related to the detergent insolubility and subcellular localization of hTDP-43 [38] This effects provides a reasonable explanation for the appearing-to-be higher motor neuron cyto-toxicity of the MT hTDP-43 forms than the WT when the cell death data from DNA transfection experiment(s) using the same amount(s) of the expression plasmids are compared (Figure 2B). In other words, overexpression of hTDP-43 is sufficient to cause dose-dependent apoptotic deaths of the motor neuronal NSC34 cells, irrespective of whether the overexpressed hTDP-43 is WT or carrying ALS-associated mutations (Figure 2B and 3B). With respect to the dose dependence, increase of the cellular level of the TDP-43 protein, with exogenous expression of either WT or MT forms of hTDP-43, by 50-200% (Table 1) would induce 5-20% of the transfected NSC34 cells to undergo apoptotic death (Figure 2B).

In interesting parallel with the dose-dependence of the cytotoxicity of hTDP-43 as derived from this study, previous transgenic mice [3944] and transgenic Drosophila[4547] experiments have suggested that elevation of the level of TDP-43, whether mutant forms or the wild type, is sufficient to cause TDP-43 proteinopathies. Also, overexpression TDP-43 in cultured human [48] and mouse cells [24, 49] induced cytotoxicity. These transgenic cell culture and animal studies are in interesting correlation with the finding of elevated levels of hTDP-43 expression in some cases of ALS and FTLD-U [50, 51]. Thus, the steady-state level of TDP-43 could be one determining factor for the occurrence and/ or progression of neurodegeneration in TDP-43 proteinopathies. Finally, since the stabilization of hTDP-43 by the ALS-associated mutations occurs in all the cell types that we have tested, it is likely that motor neuronal cells have a relatively low tolerance to the elevated amount of hTDP-43 when compared to other types of cells.

Take together all of the above, we suggest that pathogenesis of ALS could be due to the selective neurotoxicity of the spinal motor neurons caused by elevated level of hTDP-43, which in turn results from mis-regulation of the hTDP-43 metabolism due to different ALS-associated gene mutations including those within the TARDBP gene itself. How the ALS-associated mutations in hTDP-43 stabilize the protein and why the spinal motor neurons have a relatively low tolerance to the elevated level of TDP-43 remain to be investigated.

Conclusions

In conclusion, based on our data and previous transgenic TDP-43 studies in animals or cell cultures, we suggest that one major common consequence of the different ALS-associated TDP-43 mutations is the stabilization of the hTDP-43 polypeptide. The resulting elevation of the steady state level of hTDP-43 in combination with the relatively low tolerance of the spinal motor neurons to the increased amount of hTDP-43 lead to the neurodegeneration and pathogenesis of ALS, and of diseases with TDP-43 proteinopathies in general.

Declarations

Acknowledgements

We thank our lab colleagues and Ms. Sue-Ping Lee in the Confocal Microscope Core of the Institute of Molecular Biology for their help and suggestions. This research was supported by the Academia Sinica (AS) and the National Science Council of Taipei, Taiwan. C.-K. J. Shen is an AS Investigator Awardee.

Authors’ Affiliations

(1)
Institute of Molecular Medicine, National Taiwan University
(2)
Institute of Molecular Biology, Academia Sinica

References

  1. Wang HY, Wang IF, Bose J, Shen CK: Structural diversity and functional implications of the eukaryotic TDP gene family. Genomics. 2004, 83: 130-139. 10.1016/S0888-7543(03)00214-3.View ArticlePubMedGoogle Scholar
  2. Ayala YM, Pantano S, D'Ambrogio A, Buratti E, Brindisi A, Marchetti C, Romano M, Baralle FE: Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005, 348: 575-588. 10.1016/j.jmb.2005.02.038.View ArticlePubMedGoogle Scholar
  3. Ou SH, Wu F, Harrich D, Garcia-Martinez LF, Gaynor RB: Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995, 69: 3584-3596.PubMed CentralPubMedGoogle Scholar
  4. Wang IF, Wu LS, Chang HY, Shen CK: TDP-43, the signature protein of FTLD-U, is a neuronal activity-responsive factor. J Neurochem. 2008, 105: 797-806. 10.1111/j.1471-4159.2007.05190.x.View ArticlePubMedGoogle Scholar
  5. Wang IF, Reddy NM, Shen CK: Higher order arrangement of the eukaryotic nuclear bodies. Proc Natl Acad Sci U S A. 2002, 99: 13583-13588. 10.1073/pnas.212483099.PubMed CentralView ArticlePubMedGoogle Scholar
  6. Wang IF, Wu LS, Shen CK: TDP-43: an emerging new player in neurodegenerative diseases. Trends Mol Med. 2008, 14: 479-485. 10.1016/j.molmed.2008.09.001.View ArticlePubMedGoogle Scholar
  7. Buratti E, Dork T, Zuccato E, Pagani F, Romano M, Baralle FE: Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 9 skipping. EMBO J. 2001, 20: 1774-1784. 10.1093/emboj/20.7.1774.PubMed CentralView ArticlePubMedGoogle Scholar
  8. Bose JK, Wang IF, Hung L, Tarn WY, Shen CK: TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J Biol Chem. 2008, 283: 28852-28859. 10.1074/jbc.M805376200.PubMed CentralView ArticlePubMedGoogle Scholar
  9. Wu LS, Cheng WC, Hou SC, Yan YT, Jiang ST, Shen CK: TDP-43, a neuro-pathosignature factor, is essential for early mouse embryogenesis. Genesis. 2009, 48: 56-62.Google Scholar
  10. Chiang PM, Ling J, Jeong YH, Price DL, Aja SM, Wong PC: Deletion of TDP-43 down-regulates Tbc1d1, a gene linked to obesity, and alters body fat metabolism. Proc Natl Acad Sci U S A. 2010, 107: 16320-4. 10.1073/pnas.1002176107.PubMed CentralView ArticlePubMedGoogle Scholar
  11. Kraemer BC, Schuck T, Wheeler JM, Robinson LC, Trojanowski JQ, Lee VM, Schellenberg GD: Loss of murine TDP-43 disrupts motor function and plays an essential role in embryogenesis. Acta Neuropathol. 2010, 119: 409-419. 10.1007/s00401-010-0659-0.PubMed CentralView ArticlePubMedGoogle Scholar
  12. Sephton CF, Good SK, Atkin S, Dewey CM, Mayer P, Herz J, Yu G: TDP-43 is a developmentally regulated protein essential for early embryonic development. J Biol Chem. 2010, 285: 6826-6834. 10.1074/jbc.M109.061846.PubMed CentralView ArticlePubMedGoogle Scholar
  13. Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T: TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006, 351: 602-611. 10.1016/j.bbrc.2006.10.093.View ArticlePubMedGoogle Scholar
  14. Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, McCluskey LF, Miller BL, Masliah E, Mackenzie IR, Feldman H, Feiden W, Kretzschmar HA, Trojanowski JQ, Lee VM: Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006, 314: 130-133. 10.1126/science.1134108.View ArticlePubMedGoogle Scholar
  15. Lee EB, Lee VM, Trojanowski JQ: Gains or losses: molecular mechanisms of TDP43-mediated neurodegeneration. Nat Rev Neurosci. 2011, 13: 38-50.PubMed CentralPubMedGoogle Scholar
  16. Da Cruz S, Cleveland DW: Understanding the role of TDP-43 and FUS/TLS in ALS and beyond. Curr Opin Neurobiol. 2011, 21: 904-19. 10.1016/j.conb.2011.05.029.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Buratti E, Baralle FE: TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci. 2012, 37: 237-47. 10.1016/j.tibs.2012.03.003.View ArticlePubMedGoogle Scholar
  18. Wu LS, Cheng WC, Shen CK: Targeed depletion of TDP-43 expression in the spinal cord motor neurons leads to the development of amyotrophic lateral sclerosis-like phenotypes in mice. J Biol Chem. 2012, 287: 27335-44. 10.1074/jbc.M112.359000.PubMed CentralView ArticlePubMedGoogle Scholar
  19. Wijesekera LC, Leigh PN: Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009, 4: 3-10.1186/1750-1172-4-3.PubMed CentralView ArticlePubMedGoogle Scholar
  20. Pasinelli P, Brown RH: Molecular biology of amyotrophic lateral sclerosis: insights from genetics. Nat Rev Neurosci. 2006, 7: 710-723.View ArticlePubMedGoogle Scholar
  21. Geser F, Lee VM, Trojanowski JQ: Amyotrophic lateral sclerosis and frontotemporal lobar degeneration: a spectrum of TDP-43 proteinopathies. Neuropathology. 2010, 30: 103-112. 10.1111/j.1440-1789.2009.01091.x.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Kabashi E, Valdmanis PN, Dion P, Spiegelman D, McConkey BJ, Vande Velde C, Bouchard JP, Lacomblez L, Pochigaeva K, Salachas F, Pradat PF, Camu W, Meininger V, Dupre N, Rouleau GA: TARDBP mutations in individuals with sporadic and familial amyotrophic lateral sclerosis. Nat Genet. 2008, 40: 572-574. 10.1038/ng.132.View ArticlePubMedGoogle Scholar
  23. Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD: TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009, 284: 20329-20339. 10.1074/jbc.M109.010264.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Kabashi E, Lin L, Tradewell ML, Dion PA, Bercier V, Bourgouin P, Rochefort D, Bel Hadj S, Durham HD, Vande Velde C, Rouleau GA, Drapeau P: Gain and loss of function of ALS-related mutations of TARDBP (TDP-43) cause motor deficits in vivo. Hum Mol Genet. 2010, 19: 671-683. 10.1093/hmg/ddp534.View ArticlePubMedGoogle Scholar
  25. Barmada SJ, Skibinski G, Korb E, Rao EJ, Wu JY, Finkbeiner S: Cytoplasmic mislocalization of TDP-43 is toxic to neurons and enhanced by a mutation associated with familial amyotrophic lateral sclerosis. J Neurosci. 2010, 30: 639-649. 10.1523/JNEUROSCI.4988-09.2010.PubMed CentralView ArticlePubMedGoogle Scholar
  26. Duan W, Li X, Shi J, Guo Y, Li Z, Li C: Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience. 2010, 169: 1621-1629. 10.1016/j.neuroscience.2010.06.018.View ArticlePubMedGoogle Scholar
  27. Suzuki H, Lee K, Matsuoka M: TDP-43-induced death is associated with altered regulation of BIM and BCL-XL and attenuated by caspase-mediated TDP-43 cleavage. J Biol Chem. 2011, 286: 13171-83. 10.1074/jbc.M110.197483.PubMed CentralView ArticlePubMedGoogle Scholar
  28. Hengartner MO: The biochemistry of apoptosis. Nature. 2000, 407: 770-776. 10.1038/35037710.View ArticlePubMedGoogle Scholar
  29. Cashman NR, Durham HD, Blusztajn JK, Oda K, Tabira T, Shaw IT, Dahrouge S, Antel JP: Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev Dyn. 1992, 194: 209-221. 10.1002/aja.1001940306.View ArticlePubMedGoogle Scholar
  30. Matusica D, Fenech MP, Rogers ML, Rush RA: Characterization and use of the NSC-34 cell line for study of neurotrophin receptor trafficking. J Neurosci Res. 2008, 86: 553-565. 10.1002/jnr.21507.View ArticlePubMedGoogle Scholar
  31. Amano T, Richelson E, Nirenberg M: Neurotransmitter synthesis by neuroblastoma clones (neuroblast differentiation-cell culture-choline acetyltransferase- acetylcholinesterase-tyrosine hydroxylase-axons-dendrites). Proc Natl Acad Sci U S A. 1972, 69: 258-263. 10.1073/pnas.69.1.258.PubMed CentralView ArticlePubMedGoogle Scholar
  32. Suárez N, Eriksson H: Receptor-mediated endocytosis of a manganese complex of transferrin into neuroblastoma (SHSY5Y) cells in culture. J Neurochem. 1993, 61: 127-31. 10.1111/j.1471-4159.1993.tb03546.x.View ArticlePubMedGoogle Scholar
  33. Graham FL, Smiley J, Russell WC, Nairn R: Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol. 1977, 36: 59-74. 10.1099/0022-1317-36-1-59.View ArticlePubMedGoogle Scholar
  34. Kim SH, Shi Y, Hanson KA, Williams LM, Sakasai R, Bowler MJ, Tibbetts RS: Potentiation of amyotrophic lateral sclerosis (ALS)-associated TDP-43 aggregation by the proteasome-targeting factor, ubiquilin 1. J Biol Chem. 2009, 284: 8083-8092. 10.1074/jbc.M808064200.PubMed CentralView ArticlePubMedGoogle Scholar
  35. Corsten MF, Miranda R, Kasmieh R, Krichevsky AM, Weissleder R, Shah K: MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res. 2007, 67: 8994-9000. 10.1158/0008-5472.CAN-07-1045.View ArticlePubMedGoogle Scholar
  36. Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, Wei W: Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APCCdh1-mediated Skp2 destruction. Nat Cell Biol. 2009, 11: 397-408. 10.1038/ncb1847.PubMed CentralView ArticlePubMedGoogle Scholar
  37. Ling SC, Albuquerque CP, Han JS, Lagier-Tourenne C, Tokunaga S, Zhou H, Cleveland DW: ALS-associated mutations in TDP-43 increase its stability and promote TDP-43 complexes with FUS/TLS. Proc Natl Acad Sci U S A. 2010, 107: 13318-13323. 10.1073/pnas.1008227107.PubMed CentralView ArticlePubMedGoogle Scholar
  38. Watanabe S, Kaneko K, Yamanaka K: Accelerated disease onset with stabilized familial amyotrophic lateral sclerosis (ALS)-linked mutant TDP-43 proteins. J Biol Chem. 2013, 288: 3641-3654. 10.1074/jbc.M112.433615.PubMed CentralView ArticlePubMedGoogle Scholar
  39. Wegorzewska I, Bell S, Cairns NJ, Miller TM, Baloh RH: TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2009, 106: 18809-18814. 10.1073/pnas.0908767106.PubMed CentralView ArticlePubMedGoogle Scholar
  40. Tsai KJ, Yang CH, Fang YH, Cho KH, Chien WL, Wang WT, Wu TW, Lin CP, Fu WM, Shen CK: Elevated expression of TDP-43 in the forebrain of mice is sufficient to cause neurological and pathological phenotypes mimicking FTLD-U. J Exp Med. 2010, 207: 1661-1673. 10.1084/jem.20092164.PubMed CentralView ArticlePubMedGoogle Scholar
  41. Wils H, Kleinberger G, Janssens J, Pereson S, Joris G, Cuijt I, Smits V, Ceuterick-de Groote C, Van Broeckhoven C, Kumar-Singh S: TDP-43 transgenic mice develop spastic paralysis and neuronal inclusions characteristic of ALS and frontotemporal lobar degeneration. Proc Natl Acad Sci U S A. 2010, 107: 3858-3863. 10.1073/pnas.0912417107.PubMed CentralView ArticlePubMedGoogle Scholar
  42. Xu YF, Gendron TF, Zhang YJ, Lin WL, D'Alton S, Sheng H, Casey MC, Tong J, Knight J, Yu X, Rademakers R, Boylan K, Hutton M, McGowan E, Dickson DW, Lewis J, Petrucelli L: Wild-Type Human TDP-43 Expression Causes TDP-43 Phosphorylation, Mitochondrial Aggregation, Motor Deficits, and Early Mortality in Transgenic Mice. J Neurosci. 2010, 30: 10851-10859. 10.1523/JNEUROSCI.1630-10.2010.PubMed CentralView ArticlePubMedGoogle Scholar
  43. Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, Kordasiewicz HB, McAlonis-Downes M, Platoshyn O, Parone PA, Da Cruz S, Clutario KM, Swing D, Tessarollo L, Marsala M, Shaw CE, Yeo GW, Cleveland DW: ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013, 110: E736-745. 10.1073/pnas.1222809110.PubMed CentralView ArticlePubMedGoogle Scholar
  44. Zhou H, Huang C, Chen H, Wang D, Landel CP, Xia PY, Bowser R, Liu YJ, Xia XG: Transgenic rat model of neurodegeneration caused by mutation in the TDP gene. PLoS Genet. 2010, 6: e1000887-10.1371/journal.pgen.1000887.PubMed CentralView ArticlePubMedGoogle Scholar
  45. Li Y, Ray P, Rao EJ, Shi C, Guo W, Chen X, Woodruff EA, Fushimi K, Wu JY: A Drosophila model for TDP-43 proteinopathy. Proc Natl Acad Sci U S A. 2010, 107: 3169-3174. 10.1073/pnas.0913602107.PubMed CentralView ArticlePubMedGoogle Scholar
  46. Hanson KA, Kim SH, Wassarman DA, Tibbetts RS: Ubiquilin modifies TDP-43 toxicity in a Drosophila model of amyotrophic lateral sclerosis (ALS). J Biol Chem. 2010, 285: 11068-72. 10.1074/jbc.C109.078527.PubMed CentralView ArticlePubMedGoogle Scholar
  47. Lin MJ, Cheng CW, Shen CK: Neuronal function and dysfunction of Drosophila dTDP. PLoS One. 2011, 6: e20371-10.1371/journal.pone.0020371.PubMed CentralView ArticlePubMedGoogle Scholar
  48. Ash PE, Zhang YJ, Roberts CM, Saldi T, Hutter H, Buratti E, Petrucelli L, Link CD: Neurotoxic effects of TDP-43 overexpression in C. elegans. Hum Mol Genet. 2010, 19: 3206-3218. 10.1093/hmg/ddq230.PubMed CentralView ArticlePubMedGoogle Scholar
  49. Guo W, Chen Y, Zhou X, Kar A, Ray P, Chen X, Rao EJ, Yang M, Ye H, Zhu L, Liu J, Xu M, Yang Y, Wang C, Zhang D, Bigio EH, Mesulam M, Shen Y, Xu Q, Fushimi K, Wu JY: An ALS-associated mutation affecting TDP-43 enhances protein aggregation, fibril formation and neurotoxicity. Nat Struct Mol Biol. 2011, 18: 822-830. 10.1038/nsmb.2053.PubMed CentralView ArticlePubMedGoogle Scholar
  50. Mishra M, Paunesku T, Woloschak GE, Siddique T, Zhu LJ, Lin S, Greco K, Bigio EH: Gene expression analysis of frontotemporal lobar degeneration of the motor neuron disease type with ubiquitinated inclusions. Acta Neuropathol. 2007, 114: 81-94. 10.1007/s00401-007-0240-7.View ArticlePubMedGoogle Scholar
  51. Strong MJ, Volkening K, Hammond R, Yang W, Strong W, Leystra-Lantz C, Shoesmith C: TDP43 is a human low molecular weight neurofilament (hNFL) mRNA-binding protein. Mol Cell Neurosci. 2007, 35: 320-327. 10.1016/j.mcn.2007.03.007.View ArticlePubMedGoogle Scholar

Copyright

© Wu et al.; licensee BioMed Central Ltd. 2013

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Advertisement